Anti-CD19 抗体 [SJ25-C1] (Cy5 ®) (ab24845)


  • 製品名Anti-CD19 antibody [SJ25-C1] (Cy5 ®)
    CD19 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [SJ25-C1] to CD19 (Cy5 ®)
  • 標識Cy5 ®. Ex: 650nm, Em: 667nm
  • アプリケーション適用あり: Flow Cyt, IHC-Fr, IPmore details
  • 種交差性
    交差種: Human
  • 免疫原

    The details of the immunogen for this antibody are not available.

  • 特記事項This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited. This material is also subject to proprietary rights of GE Healthcare Bio-Sciences Corp. and Carnegie Mellon University and made and sold under License from GE Healthcare Bio-Sciences Corp. This product is licensed for sale only for research. It is NOT licensed for any other use. There is no implied license hereunder for any commercial use. COMMERCIAL USE shall include: 1 Sale, lease, license or other transfer of the material or any material derived or produced from it. 2 Sale, lease, license or other grant of rights to use this material or any material derived or produced from it. 3 Use of this material to perform services for a fee for third parties. If you require a commercial license to use this material and do not have one, please return this material, unopened to Abcam Plc of 330 Cambridge Science Park, Cambridge, CB4 0FL, and any money paid for the material will be refunded.



Our Abpromise guarantee covers the use of ab24845 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Flow Cyt Use 10µl for 106 cells.

ab154444 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

IHC-Fr Use at an assay dependent concentration.
IP Use at an assay dependent concentration.


  • 機能Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
  • 関連疾患Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
  • 配列類似性Contains 2 Ig-like C2-type (immunoglobulin-like) domains.
  • 翻訳後修飾Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
  • 細胞内局在Membrane.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Antibody deficiency due to defect in CD19, included antibody
    • AW495831 antibody
    • B lymphocyte antigen CD19 antibody
    • B lymphocyte surface antigen B4 antibody
    • B-lymphocyte antigen CD19 antibody
    • B-lymphocyte surface antigen B4 antibody
    • B4 antibody
    • CD19 antibody
    • CD19 antigen antibody
    • CD19 molecule antibody
    • Cd19 protein antibody
    • CD19_HUMAN antibody
    • CVID3 antibody
    • Differentiation antigen CD19 antibody
    • Leu 12 antibody
    • Leu-12 antibody
    • Leu12 antibody
    • MGC109570 antibody
    • MGC12802 antibody
    • T-cell surface antigen Leu-12 antibody
    see all

Anti-CD19 antibody [SJ25-C1] (Cy5 ®) (ab24845) 使用論文

ab24845 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab24845.
Please use the links above to contact us or submit feedback about this product.